Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!

Bone Marrow Transplantation volume 49, pages 599–606 (2014)Cite this article

Subjects

Abstract

Hodgkin lymphoma (HL) relapsing after an autologous hematopoietic cell transplant (HCT) poses a therapeutic challenge. In this setting, salvage chemotherapy (for example, gemcitabine-based, ifosfamide-containing and others) or immunotherapy (for example, brentuximab vedotin) is essential as a bridging-cytoreduction strategy to an allogeneic HCT. Myeloablative allogeneic hematopoietic cell transplantation in relapsed HL is associated with high rates of non-relapse mortality. In carefully selected patients with chemosensitive disease, allografting following lower-intensity conditioning regimens can provide durable disease control rates of about 25–35%. Promising early results with haploidentical and umbilical cord transplantation are noteworthy and are expanding this procedure to patients for whom HLA-matched related or unrelated donors are not available. Unfortunately, a significant number of HL patients relapsing after an autologous HCT are not candidates for allografting because of the presence of resistant disease, donor unavailability or comorbidities. Brentuximab vedotin is approved for HL relapsing after a prior autograft. Rituximab and bendamustine are also active in this setting, albeit with short durations of remission. Histone deacetylase inhibitors (for example, panobinostat, mocetinostat), mTOR inhibitors (for example, everolimus) and immunomodulatory agents (lenalidomide) have shown activity in phase II trials, but currently are not approved for this indication. Second autologous HCT are rarely performed but this approach should not be considered standard practice at this time. The need for effective agents for post autograft failures of HL largely remains unmet. Continuous efforts to ensure early referral of such patients for allogeneic HCT or investigational therapies are the key to improving outcomes of this not-so-good lymphoma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051–1054.

    Article  CAS  Google Scholar 

  2. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002; 359: 2065–2071.

    Article  CAS  Google Scholar 

  3. Bierman PJ, Lynch JC, Bociek RG, Whalen VL, Kessinger A, Vose JM et al. The International Prognostic Factors Project score for advanced Hodgkin’s disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 2002; 13: 1370–1377.

    Article  CAS  Google Scholar 

  4. Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton DM et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin’s disease: importance of disease status at transplant. J Clin Oncol 1993; 11: 704–711.

    Article  CAS  Google Scholar 

  5. Porter DL, Stadtmauer EA, Lazarus HM . ‘GVHD’: graft-versus-host disease or graft-versus-Hodgkin’s disease? An old acronym with new meaning. Bone Marrow Transplant 2003; 31: 739–746.

    Article  CAS  Google Scholar 

  6. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 2007; 109: 2481–2489.

    Article  Google Scholar 

  7. Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010; 116: 4934–4937.

    Article  CAS  Google Scholar 

  8. Akhtar S, Al-Sugair AS, Abouzied M, Alkadhi Y, Dingle M, Abdelsalam M et al. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin’s lymphoma: outcome after high-dose chemotherapy and auto-SCT. Bone Marrow Transplant 2013; 48: 1530–1536.

    Article  CAS  Google Scholar 

  9. Palmer J, Goggins T, Broadwater G, Chao N, Horwitz M, Beaven A et al. Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant 2011; 46: 847–851.

    Article  CAS  Google Scholar 

  10. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812–1821.

    Article  CAS  Google Scholar 

  11. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012; 30: 2183–2189.

    Article  CAS  Google Scholar 

  12. Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S et al. Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. J Clin Oncol 2000; 18: 2615–2619.

    Article  CAS  Google Scholar 

  13. Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol 2007; 18: 1071–1079.

    Article  CAS  Google Scholar 

  14. Currin ES, Gopal AK . Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation. Korean J Hematol 2012; 47: 8–16.

    Article  CAS  Google Scholar 

  15. Baetz T, Belch A, Couban S, Imrie K, Yau J, Myers R et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003; 14: 1762–1767.

    Article  CAS  Google Scholar 

  16. Gopal AK, Press OW, Shustov AR, Petersdorf SH, Gooley TA, Daniels JT et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma 2010; 51: 1523–1529.

    Article  CAS  Google Scholar 

  17. Blum KA, Jung SH, Johnson JL, Lin TS, Hsi ED, Lucas DM et al. Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcgammaRIIIa-158 V/F polymorphism. Ann Oncol 2010; 21: 2246–2254.

    Article  CAS  Google Scholar 

  18. Goldenberg MM . Pharmaceutical approval update. P T 2008; 33: 299–302.

    PubMed  PubMed Central  Google Scholar 

  19. Borchmann P, Schnell R, Diehl V, Engert A . New drugs in the treatment of Hodgkin’s disease. Ann Oncol 1998; 9 (Suppl 5): S103–S108.

    Article  Google Scholar 

  20. Corazzelli G, Angrilli F, D’Arco A, Ferrara F, Musto P, Guarini A et al. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol 2013; 160: 207–215.

    Article  CAS  Google Scholar 

  21. Moskowitz AJ, Hamlin PA Jr., Perales MA, Gerecitano J, Horwitz SM, Matasar MJ et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013; 31: 456–460.

    Article  CAS  Google Scholar 

  22. Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25: 2764–2769.

    Article  CAS  Google Scholar 

  23. Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009; 146: 171–179.

    Article  CAS  Google Scholar 

  24. Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012; 119: 6379–6381.

    Article  CAS  Google Scholar 

  25. Eichenauer DA, Fuchs M, Pluetschow A, Klimm B, Halbsguth T, Boll B et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2011; 118: 4363–4365.

    Article  CAS  Google Scholar 

  26. Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rudiger T et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008; 111: 109–111.

    Article  CAS  Google Scholar 

  27. Ramchandren R . Advances in the treatment of relapsed or refractory Hodgkin’s lymphoma. Oncologist 2012; 17: 367–376.

    Article  CAS  Google Scholar 

  28. Oki Y, Younes A . Does rituximab have a place in treating classic hodgkin lymphoma? Curr Hematol Malig Rep 2010; 5: 135–139.

    Article  Google Scholar 

  29. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003; 98: 310–314.

    Article  CAS  Google Scholar 

  30. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011; 117: 5827–5834.

    Article  CAS  Google Scholar 

  31. Bolden JE, Peart MJ, Johnstone RW . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769–784.

    Article  CAS  Google Scholar 

  32. Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008; 112: 1424–1433.

    Article  CAS  Google Scholar 

  33. Dickinson M, Ritchie D, DeAngelo DJ, Spencer A, Ottmann OG, Fischer T et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol 2009; 147: 97–101.

    Article  CAS  Google Scholar 

  34. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012; 30: 2197–2203.

    Article  CAS  Google Scholar 

  35. Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S et al. Mocetinostat for relapsed classical Hodgkin’s lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011; 12: 1222–1228.

    Article  CAS  Google Scholar 

  36. Kirschbaum MH, Goldman BH, Zain JM, Cook JR, Rimsza LM, Forman SJ et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma 2012; 53: 259–262.

    Article  CAS  Google Scholar 

  37. Atadja P . Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 2009; 280: 233–241.

    Article  CAS  Google Scholar 

  38. Lemoine M, Derenzini E, Buglio D, Medeiros LJ, Davis RE, Zhang J et al. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood 2012; 119: 4017–4025.

    Article  CAS  Google Scholar 

  39. Christian B, Kopko A, Fehniger TA, Bartlett NL, Blum KAA, Phase I . Trial of the histone deacetylase (HDAC) inhibitor, panobinostat, in combination with lenalidomide in patients with relapsed/refractory Hodgkin’s lymphoma (HL). ASH Ann Meet Abstr 2012; 120: 1644.

    Google Scholar 

  40. Schmitz R, Stanelle J, Hansmann ML, Kuppers R . Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol 2009; 4: 151–174.

    Article  CAS  Google Scholar 

  41. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85: 320–324.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Halling T, Wellik LE et al. Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. Am J Hematol 2012; 87: 277–283.

    Article  CAS  Google Scholar 

  43. Chiang CT, Yeh PY, Gao M, Chen CW, Yeh LC, Feng WC et al. Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma. Cancer Lett 2010; 298: 195–203.

    Article  CAS  Google Scholar 

  44. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011; 118: 5119–5125.

    Article  CAS  Google Scholar 

  45. Kuruvilla J, Taylor D, Wang L, Blattler C, Keating A, Crump M . Phase II trial of Lenalidomide in patients with relapsed or refractory Hodgkin lymphoma. ASH Ann Meet Abstr 2008; 112: 3052.

    Google Scholar 

  46. Boll B, Fuchs M, Reiners KS, Engert A, Borchmann P . Lenalidomide in patients with relapsed or refractory Hodgkin lymphoma. ASH Ann Meet Abstr 2010; 116: 2828.

    Google Scholar 

  47. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Hurd DD, Blum KA et al. A phase 2 multicenter study of continuous dose lenalidomide in relapsed or refractory classical Hodgkin lymphoma. ASH Ann Meet Abstr 2012; 120: 1623.

    Google Scholar 

  48. Barrett AJ, Savani BN . Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20: 1661–1672.

    Article  CAS  Google Scholar 

  49. Crocchiolo R, Castagna L, Furst S, El-Cheikh J, Faucher C, Oudin C et al. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin’s lymphoma. Bone Marrow Transplant 2013; 48: 249–252.

    Article  CAS  Google Scholar 

  50. Kharfan-Dabaja MA, Bazarbachi A . Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens. Cancer Control 2012; 19: 68–75.

    Article  Google Scholar 

  51. Hamadani M, Mohty M, Kharfan-Dabaja MA . Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. Cancer Control 2011; 18: 237–245.

    Article  Google Scholar 

  52. Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21-year Seattle experience. J Clin Oncol 1993; 11: 2342–2350.

    Article  CAS  Google Scholar 

  53. Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol 1996; 14: 572–578.

    Article  CAS  Google Scholar 

  54. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH . Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996; 14: 1291–1296.

    Article  CAS  Google Scholar 

  55. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fluckiger U, Frere P et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplant 2011; 46: 709–718.

    Article  CAS  Google Scholar 

  56. Dignan FL, Greenblatt D, Cox M, Cavenagh J, Oakervee H, Apperley JF et al. Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD. Bone Marrow Transplant 2012; 47: 824–830.

    Article  CAS  Google Scholar 

  57. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667–678.

    Article  CAS  Google Scholar 

  58. Feinstein L, Sandmaier B, Maloney D, McSweeney PA, Maris M, Flowers C et al. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Ann NY Acad Sci 2001; 938: 328–337 discussion 337-9.

    Article  CAS  Google Scholar 

  59. Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J et al. Phase II study of CD4(+)-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. Biol Blood Marrow Transplant 2013; 19: 1087–1093.

    Article  CAS  Google Scholar 

  60. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 455–462.

    Article  CAS  Google Scholar 

  61. Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009; 94: 230–238.

    Article  Google Scholar 

  62. Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010; 115: 3671–3677.

    Article  CAS  Google Scholar 

  63. Thomson KJ, Peggs KS, Smith P, Cavet J, Hunter A, Parker A et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin’s lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008; 41: 765–770.

    Article  CAS  Google Scholar 

  64. Todisco E, Castagna L, Sarina B, Mazza R, Anastasia A, Balzarotti M et al. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin’s disease after high-dose chemotherapy and autologous stem cell infusion. Eur J Haematol 2007; 78: 322–329.

    Article  CAS  Google Scholar 

  65. Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D et al. Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365: 1934–1941.

    Article  Google Scholar 

  66. Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006; 12: 172–183.

    Article  Google Scholar 

  67. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008; 93: 257–264.

    Article  CAS  Google Scholar 

  68. Majhail NS, Weisdorf DJ, Wagner JE, Defor TE, Brunstein CG, Burns LJ . Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 2006; 107: 3804–3807.

    Article  CAS  Google Scholar 

  69. Burroughs LM, O'Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 1279–1287.

    Article  Google Scholar 

  70. Devetten MP, Hari PN, Carreras J, Logan BR, van Besien K, Bredeson CN et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2009; 15: 109–117.

    Article  Google Scholar 

  71. Johansson JE, Remberger M, Lazarevic V, Hallbook H, Wahlin A, Kimby E et al. Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin’s lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder. Bone Marrow Transplant 2011; 46: 870–875.

    Article  CAS  Google Scholar 

  72. Mo XD, Xu LP, Liu DH, Chen YH, Han W, Zhang XH et al. Patients receiving HLA-haploidentical/partially matched related allo-HSCT can achieve desirable health-related QoL that is comparable to that of patients receiving HLA-identical sibling allo-HSCT. Bone Marrow Transplant 2012; 47: 1201–1205.

    Article  Google Scholar 

  73. Kindwall-Keller TL, Hegerfeldt Y, Meyerson HJ, Margevicius S, Fu P, van Heeckeren W et al. Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies. Bone Marrow Transplant 2012; 47: 924–933.

    Article  CAS  Google Scholar 

  74. Vose JM, Bierman PJ, Anderson JR, Kessinger A, Pierson J, Nelson J et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992; 80: 2142–2148.

    CAS  PubMed  Google Scholar 

  75. Vandenberghe E, Pearce R, Taghipour G, Fouillard L, Goldstone AH . Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry. J Clin Oncol 1997; 15: 1595–1600.

    Article  CAS  Google Scholar 

  76. Lin TS, Avalos BR, Penza SL, Marcucci G, Elder PJ, Copelan EA . Second autologous stem cell transplant for multiply relapsed Hodgkin’s disease. Bone Marrow Transplant 2002; 29: 763–767.

    Article  CAS  Google Scholar 

  77. Smith SM, van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO et al. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant 2008; 14: 904–912.

    Article  Google Scholar 

  78. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Ledesma C, Andersson BS et al. Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. Leuk Lymphoma 2012; 53: 1239–1241.

    Article  Google Scholar 

  79. El-Jurdi N, Reljic T, Kumar A, Pidala J, Bazarbachi A, Djulbegovic B et al. Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. Immunotherapy 2013; 5: 457–466.

    Article  CAS  Google Scholar 

  80. Theurich S, Malcher J, Wennhold K, Shimabukuro-Vornhagen A, Chemnitz J, Holtick U et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol 2013; 31: e59–e63.

    Article  Google Scholar 

  81. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med 2010; 362: 875–885.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Supported in part by Conquer Cancer Foundation of ASCO Career Development Award (MH) and ASBMT New Investigator Award (MH).

Author information

Authors and Affiliations

  1. Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, FL, USA

    M A Kharfan-Dabaja

  2. Department of Oncologic Sciences, University of South Florida College of Medicine, Tampa, FL, USA

    M A Kharfan-Dabaja

  3. Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA

    M Hamadani

  4. Department of Hematology-Oncology, Princess Margaret Hospital, Toronto, ON, Canada

    H Sibai

  5. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

    B N Savani

Authors
  1. M A Kharfan-Dabaja
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Hamadani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Sibai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B N Savani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M A Kharfan-Dabaja.

Ethics declarations

Competing interests

The authors declare no conflict of interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kharfan-Dabaja, M., Hamadani, M., Sibai, H. et al. Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!. Bone Marrow Transplant 49, 599–606 (2014). https://doi.org/10.1038/bmt.2013.226

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2013.226

Keywords

This article is cited by

Search

Advanced search

Quick links